Many readers will remember that there was an issue last year with topical steroids manufactured by GSK, resulting in a lack of availability for a number of months. This was resolved, however there continues to be an ongoing and separate issue with one particular steroid, Trimovate. We have received the following statement from GSK:
“GSK has identified an issue with one active pharmaceutical ingredient used to produce Trimovate (clobetasone oxytetracycline nystatin) at one of our GSK facilities.
We sincerely apologise for any inconvenience this supply constraint is causing patients. Patient safety is always our priority, and patients rightly need to be able to have trust in our products. We are committed to delivering medicines and products that are made to the highest standards. For this reason, we are not releasing Trimovate from the manufacturing site until we have investigated the cause and the scope of the problem.
We are doing our utmost to bring the supply of Trimovate back to normal as soon as possible which we anticipate will be by early 2017. In the meantime, patients should seek advice from their healthcare professional on suitable, alternative treatment options.”
Trimovate is unique as it combines a corticosteroid with an antifungal and an antibiotic, making it good for treating inflammatory skin conditions where there is also a bacterial or fungal condition present. It is not a treatment that would be regularly used for psoriasis where no infection is present, however it may be particularly useful for psoriasis in the sensitive or intimate areas, which are more prone to infection. If you are prescribed Trimovate by your GP or Dermatologist, do make them aware of the current manufacturing issues so that they can prescribe an alternative or alternatives.
Should you wish to discuss any further with the manufacturer please contact GSK Customer Relations on 0800 783 8881 or email@example.com